TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages

  Grada, Zakaria ^a,b   Hegde, Meenakshi ^a,b   Byrd, Tiara ^a,b   Shaffer, Donald R ^a,b   Ghazi, Alexia ^a,b   Brawley, Vita S ^a,b   Corder, Amanda ^a,b   Schönfeld, Kurt ^c   Koch, Joachim ^c   Dotti, Gianpietro ^a,b   Heslop, Helen E ^a,b   Gottschalk, Stephen ^a,b   Wels, Winfried S ^c   Baker, Matthew L ^b   Ahmed, Nabil ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

bispecific chimeric antigen receptor; cancer immunotherapy; CAR; molecular modeling; T cell therapy

Indexed keywords

ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; TANDEM CHIMERIC ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; EFFECTOR CELL; FEASIBILITY STUDY; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; MALE; MOLECULAR DOCKING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; TRANSGENE;

EID: 84880259439     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.32     Document Type: Article

References (51)

1. Kochenderfer, JN and Rosenberg, SA (2011). Chimeric antigen receptor-modified T cells in CLL. N Engl J Med 365: 1937-8; author reply 1938.
2. Eshhar, Z, Waks, T, Gross, G and Schindler, DG (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90: 720-724. (Pubitemid 23028937)
3. Sadelain, M, Rivière, I and Brentjens, R (2003). Targeting tumours with genetically enhanced Tlymphocytes. Nat Rev Cancer 3: 35-45. (Pubitemid 37328885)
4. Brentjens, RJ, Latouche, JB, Santos, E, Marti, F, Gong, MC, Lyddane, C et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human Tlymphocytes costimulated by CD80 and interleukin-15. Nat Med 9: 279-286. (Pubitemid 36362782)
5. Pule, M, Straathof, K, Dotti, G, Heslop, HE, Rooney, CM, Brenner, MK (2004). Threemodule signaling endo-domain artificial T-cell receptor which transmits CD28, OX40 and CD3-zeta signals enhances IL-2 release and proliferative response in transduced primary T-cells. Blood 104:485a.
6. Savoldo, B, Ramos, CA, Liu, E, Mims, MP, Keating, MJ, Carrum, G et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
7. Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G et al. (2008). Virusspecific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
8. Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
9. Jensen, MC, Popplewell, L, Cooper, LJ, DiGiusto, D, Kalos, M, Ostberg, JR et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245-1256.
10. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
11. Dunn, GP, Old, LJ and Schreiber, RD (2004). The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360. (Pubitemid 38680426)
12. Weijtens, ME, Hart, EH and Bolhuis, RL (2000). Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 7: 35-42. (Pubitemid 30077147)
13. Buchner, GS, Murphy, RD, Buchete, NV and Kubelka, J (2011). Dynamics of protein folding: probing the kinetic network of folding-unfolding transitions with experiment and theory. Biochim Biophys Acta 1814: 1001-1020.
14. Kuhlman, B and Baker, D (2004). Exploring folding free energy landscapes using computational protein design. Curr Opin Struct Biol 14: 89-95. (Pubitemid 38249597)
15. Perez-Aguilar, JM and Saven, JG (2012). Computational design of membrane proteins. Structure 20: 5-14.
16. Samish, I, MacDermaid, CM, Perez-Aguilar, JM and Saven, JG (2011). Theoretical and computational protein design. Annu Rev Phys Chem 62: 129-149.
17. Kiel, C, Beltrao, P and Serrano, L (2008). Analyzing protein interaction networks using structural information. Annu Rev Biochem 77: 415-441.
18. M atsushima, N, Yoshida, H, Kumaki, Y, Kamiya, M, Tanaka, T, Izumi, Y et al. (2008). Flexible structures and ligand interactions of tandem repeats consisting of proline, glycine, asparagine, serine, and/or threonine rich oligopeptides in proteins. Curr Protein Pept Sci 9: 591-610.
19. Ahmed, N, Salsman, VS, Kew, Y, Shaffer, D, Powell, S, Zhang, YJ et al. (2010). HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16: 474-485.
20. Pieper, U, Webb, BM, Barkan, DT, Schneidman-Duhovny, D, Schlessinger, A, Braberg, H et al. (2011). ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res 39(Database issue): D465-D474.
21. Cho, HS, Mason, K, Ramyar, KX, Stanley, AM, Gabelli, SB, Denney, DW Jr et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760. (Pubitemid 36227628)
22. Shim, AH, Liu, H, Focia, PJ, Chen, X, Lin, PC and He, X (2010). Structures of a plateletderived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci USA 107: 11307-11312.
23. Schneidman-Duhovny, D, Inbar, Y, Nussinov, R and Wolfson, HJ (2005). PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33(Web Server issue): W363-W367. (Pubitemid 44529944)
24. Andrusier, N, Nussinov, R and Wolfson, HJ (2007). FireDock: fast interaction refinement in molecular docking. Proteins 69: 139-159. (Pubitemid 47339146)
25. Gerstmayer, B, Altenschmidt, U, Hoffmann, M and Wels, W (1997). Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J Immunol 158: 4584-4590. (Pubitemid 127483776)
26. Raab, D, Graf, M, Notka, F, Schödl, T and Wagner, R (2010). The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol 4: 215-225.
27. Rossig, C, Bollard, CM, Nuchtern, JG, Merchant, DA and Brenner, MK (2001). Targeting of G(D2)-positive tumor cells by human Tlymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 94: 228-236. (Pubitemid 32911418)
28. Ahmed, N, Ratnayake, M, Savoldo, B, Perlaky, L, Dotti, G, Wels, WS et al. (2007). Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67: 5957-5964. (Pubitemid 46985032)
29. Pettersen, EF, Goddard, TD, Huang, CC, Couch, GS, Greenblatt, DM, Meng, EC et al. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
30. Zhou, X, Vink, M, Klaver, B, Berkhout, B and Das, AT (2006). Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther 13: 1382-1390. (Pubitemid 44420633)
31. Ahmed, N, Salsman, VS, Yvon, E, Louis, CU, Perlaky, L, Wels, WS et al. (2009). Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17: 1779-1787.
32. Bargou, R, Leo, E, Zugmaier, G, Klinger, M, Goebeler, M, Knop, S et al. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977.
33. Hagemeyer, CE, von Zur Muhlen, C, von Elverfeldt, D and Peter, K (2009). Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 101: 1012-1019.
34. Wu, C, Ying, H, Grinnell, C, Bryant, S, Miller, R, Clabbers, A et al. (2007). Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25: 1290-1297. (Pubitemid 350076510)
35. Gu, J and Ghayur, T (2012). Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Meth Enzymol 502: 25-41.
36. Doppalapudi, VR, Huang, J, Liu, D, Jin, P, Liu, B, Li, L et al. (2010). Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 107: 22611-22616.
37. Duchnowska, R and Szczylik, C (2005). Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 31: 312-318. (Pubitemid 41001678)
38. Shmueli, E, Wigler, N and Inbar, M (2004). Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40: 379-382. (Pubitemid 38121275)
39. Verneris, MR, Arshi, A, Edinger, M, Kornacker, M, Natkunam, Y, Karami, M et al. (2005). Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokineinduced killer cells. Clin Cancer Res 11: 4561-4570. (Pubitemid 40825647)
40. Hong, JJ, Rosenberg, SA, Dudley, ME, Yang, JC, White, DE, Butman, JA et al. (2010). Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 16: 4892-4898.
41. Study of administration of CMV-specific cytotoxic Tlymphocytes expressing CAR targeting HER2 in patients with GBM (HERT-GBM). (2011). http://clinicaltrials.gov/ct2/show/NCT01109095?term=HERT-GBM&rank=1
42. Patel, SD, Moskalenko, M, Tian, T, Smith, D, McGuinness, R, Chen, L et al. (2000). T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Ther 7: 1127-1134. (Pubitemid 30661031)
43. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
44. Wilkie, S, van Schalkwyk, MC, Hobbs, S, Davies, DM, van der Stegen, SJ, Pereira, AC et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32: 1059-1070.
45. Calarese, DA, Scanlan, CN, Zwick, MB, Deechongkit, S, Mimura, Y, Kunert, R et al. (2003). Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071. (Pubitemid 36760127)
46. Kleinjung, J, Petit, MC, Orlewski, P, Mamalaki, A, Tzartos, SJ, Tsikaris, V et al. (2000). The third-dimensional structure of the complex between an Fv antibody fragment and an analogue of the main immunogenic region of the acetylcholine receptor: a combined twodimensional NMR, homology, and molecular modeling approach. Biopolymers 53: 113-128. (Pubitemid 30077672)
47. Leysath, CE, Monzingo, AF, Maynard, JA, Barnett, J, Georgiou, G, Iverson, BL et al. (2009). Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J Mol Biol 387: 680-693.
48. Wilkinson, IC, Hall, CJ, Veverka, V, Shi, JY, Muskett, FW, Stephens, PE et al. (2009). High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development. J Biol Chem 284: 31928-31935.
49. Ginalski, K, Elofsson, A, Fischer, D and Rychlewski, L (2003). 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics 19: 1015-1018. (Pubitemid 36675823)
50. Zola, H, MacArdle, PJ, Bradford, T, Weedon, H, Yasui, H and Kurosawa, Y (1991). Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 69 (Pt 6): 411-422.
51. Wels, W, Harwerth, IM, Zwickl, M, Hardman, N, Groner, B and Hynes, NE (1992). Construction, bacterial expression and characterization of a bifunctional singlechain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology (NY) 10: 1128-1132.